ID   Tat-1
AC   CVCL_M789
SY   TAT-1
DR   Wikidata; Q54971735
RX   PubMed=11840295;
RX   PubMed=26727417;
CC   Doubling time: 72 hours (PubMed=11840295).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Axillary lymph node; UBERON=UBERON_0001097.
DI   NCIt; C3209; Follicular lymphoma
DI   ORDO; Orphanet_545; Follicular lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 29-06-23; Version: 9
//
RX   PubMed=11840295; DOI=10.1038/sj.leu.2402372;
RA   Denyssevych, Tetyana
RA   Lestou, Valia S.
RA   Knesevich, S.
RA   Robichaud, Marc
RA   Salski, Chris
RA   Tan, Ru-Sung
RA   Gascoyne, Randy D.
RA   Horsman, Douglas E.
RA   Mayer, Lawrence D.
RT   "Establishment and comprehensive analysis of a new human transformed
RT   follicular lymphoma B cell line, Tat-1.";
RL   Leukemia 16:276-283(2002).
//
RX   PubMed=26727417; DOI=10.3109/10428194.2015.1108414;
RA   Drexler, Hans Gunther
RA   Eberth, Sonja
RA   Nagel, Stefan
RA   MacLeod, Roderick A.F.
RT   "Malignant hematopoietic cell lines: in vitro models for double-hit
RT   B-cell lymphomas.";
RL   Leuk. Lymphoma 57:1015-1020(2016).
//